Bagheri Baharak, Maurer Alan H, Cone Libby, Doss Mohan, Adler Lee
Department of Diagnostic Imaging, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
J Nucl Med. 2004 Aug;45(8):1340-3.
Prior studies have documented increased (18)F-FDG adrenal activity in both benign and malignant pathologic conditions. When whole-body PET imaging is performed without CT anatomic coregistration, however, the normal adrenal gland is difficult to recognize. The purpose of this study was to investigate the normal adrenal appearance and standardized uptake value (SUV) using (18)F-FDG PET/CT imaging.
Twenty patients with lymphoma with normal-appearing adrenal glands on prior CT examination (less than a 5% pretest likelihood of adrenal involvement) were studied. PET/CT imaging was performed 2 h after intravenous administration of (18)F-FDG. Unenhanced CT scans were acquired for attenuation correction and anatomic coregistration. PET images were reconstructed using an ordered-subsets expectation maximization algorithm and were corrected for body weight, dose, and radioactive decay. Ability to confirm visualization of the adrenal glands was determined for (18)F-FDG PET alone and for (18)F-FDG PET/CT by a consensus of 2 readers, and uptake of (18)F-FDG in the adrenal gland was compared with liver activity and scored visually (0 = no visualization, 1 = activity less than in liver, 2 = activity equal to liver activity, and 3 = activity greater than in liver).
The 2 readers agreed on visualization of the adrenal glands with PET alone for 2 of 40 (5%) glands. With PET/CT, the readers agreed on visualization of 27 of 40 (68%) adrenal glands. Visual scores for normal adrenal activity ranged from 0 to 3, and maximum SUVs ranged from 0.95 to 2.46. Visual scoring of adrenal activity correlated well with both mean and maximal SUV (mean SUV vs. visual score: slope = 0.96, r = 0.88; maximum SUV vs. visual score: slope = 0.99, r = 0.87).
PET/CT permits more reliable visualization of normal adrenal glands than does PET alone. Visual assessment of adrenal uptake correlates well with SUV measurement, and readers of PET/CT need to be aware of the wide range of normal adrenal uptake.
先前的研究已记录到在良性和恶性病理状况下,肾上腺的(18)F-FDG活性均增加。然而,当在没有CT解剖配准的情况下进行全身PET成像时,正常肾上腺很难识别。本研究的目的是使用(18)F-FDG PET/CT成像来研究正常肾上腺的表现及标准化摄取值(SUV)。
对20例先前CT检查显示肾上腺外观正常(肾上腺受累的预测试可能性小于5%)的淋巴瘤患者进行研究。静脉注射(18)F-FDG后2小时进行PET/CT成像。获取未增强CT扫描用于衰减校正和解剖配准。PET图像使用有序子集期望最大化算法重建,并针对体重、剂量和放射性衰变进行校正。由2位阅片者达成共识,确定单独的(18)F-FDG PET以及(18)F-FDG PET/CT对肾上腺的显示能力,并将肾上腺中(18)F-FDG的摄取与肝脏活性进行比较并进行视觉评分(0 =未显示,1 =活性低于肝脏,2 =活性等于肝脏活性,3 =活性高于肝脏)。
2位阅片者对于单独PET显示的40个肾上腺中的2个(5%)达成一致意见。对于PET/CT,阅片者对于40个肾上腺中的27个(68%)达成一致意见。正常肾上腺活性的视觉评分范围为0至3,最大SUV范围为0.95至2.46。肾上腺活性的视觉评分与平均和最大SUV均具有良好的相关性(平均SUV与视觉评分:斜率=0.96,r = 0.88;最大SUV与视觉评分:斜率=0.99,r = 0.87)。
与单独的PET相比,PET/CT能更可靠地显示正常肾上腺。肾上腺摄取的视觉评估与SUV测量具有良好的相关性,PET/CT的阅片者需要了解正常肾上腺摄取的广泛范围。